Yan Zhao1, Jenil Patel2, Ying Huang3, Lijuan Yin4, Lei Tang5. 1. Department of Pediatrics, People's Hospital of Chongqing Banan District, Chongqing 401320, China. Electronic address: zhaoyanwow@126.com. 2. Department of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, Dallas, TX, USA. 3. Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China. 4. Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China. Electronic address: yudishengyin4356@sina.com. 5. Department of Pediatrics, People's Hospital of Chongqing Banan District, Chongqing 401320, China. Electronic address: tangleicqums@163.com.
Abstract
OBJECTIVE: A meta-analysis of laboratory cardiac markers for multisystem inflammatory syndrome in children (MIS-C) was performed in patients with coronavirus disease 2019 (COVID-19). METHODS: Eight databases were searched until April 10, 2021, for studies on cardiac markers, including B-type natriuretic peptide (BNP)/N-terminal pro-BNP (NT-proBNP), troponin, aspartate aminotransferase (AST), in MIS-C patients. RESULTS: Of the 2583 participants enrolled in 24 studies, 1613 patients were diagnosed with MIS-C. MIS-C patients exhibited higher BNP levels than patients with non-severe COVID-19 [SMD (95% CI): 1.13 (0.48, 1.77), p < 0.05]. No significant differences in BNP levels were observed between patients with MIS-C and severe COVID-19 [SMD (95% CI): 0.29 (-0.07, 0.65), p = 0.117]. Comparisons of MIS-C patients to all COVID-19 patients revealed no significant differences in levels of troponin [SMD (95% CI): 0.13 (-0.07, 0.32), p = 0.212] or AST [SMD (95% CI): 0.10 (-0.11, 0.31), p = 0.336]. Compared to patients with non-severe MIS-C, those with severe MIS-C exhibited higher levels of BNP [SMD (95% CI): 0.26 (0.04, 0.48), p < 0.05], but no differences in troponin [SMD (95% CI): 0.05 (-0.06, 0.16) p = 0.387] or AST [SMD (95% CI): 0.19 (-0.34, 0.71), p = 0.483] were observed. Moreover, there was no significant difference in BNP [SMD (95% CI): -0.21 (-1.07, 0.64), p = 0.624] or troponin [SMD (95% CI): -0.07 (-0.45, 0.31), p = 0.710] between MIS-C with and without coronary artery abnormality. Sensitivity analyses were performed to assess stability. No publication bias was detected based on Begg's test. CONCLUSIONS: The key cardiac marker that showed differences between patients with MIS-C/non-severe COVID-19 and between patients with severe/non-severe MIS-C was BNP. Other markers, such as troponin and AST, did not exhibit notable differences in indicating cardiac injury between patients with MIS-C and COVID-19.
OBJECTIVE: A meta-analysis of laboratory cardiac markers for multisystem inflammatory syndrome in children (MIS-C) was performed in patients with coronavirus disease 2019 (COVID-19). METHODS: Eight databases were searched until April 10, 2021, for studies on cardiac markers, including B-type natriuretic peptide (BNP)/N-terminal pro-BNP (NT-proBNP), troponin, aspartate aminotransferase (AST), in MIS-C patients. RESULTS: Of the 2583 participants enrolled in 24 studies, 1613 patients were diagnosed with MIS-C. MIS-C patients exhibited higher BNP levels than patients with non-severe COVID-19 [SMD (95% CI): 1.13 (0.48, 1.77), p < 0.05]. No significant differences in BNP levels were observed between patients with MIS-C and severe COVID-19 [SMD (95% CI): 0.29 (-0.07, 0.65), p = 0.117]. Comparisons of MIS-C patients to all COVID-19patients revealed no significant differences in levels of troponin [SMD (95% CI): 0.13 (-0.07, 0.32), p = 0.212] or AST [SMD (95% CI): 0.10 (-0.11, 0.31), p = 0.336]. Compared to patients with non-severe MIS-C, those with severe MIS-C exhibited higher levels of BNP [SMD (95% CI): 0.26 (0.04, 0.48), p < 0.05], but no differences in troponin [SMD (95% CI): 0.05 (-0.06, 0.16) p = 0.387] or AST [SMD (95% CI): 0.19 (-0.34, 0.71), p = 0.483] were observed. Moreover, there was no significant difference in BNP [SMD (95% CI): -0.21 (-1.07, 0.64), p = 0.624] or troponin [SMD (95% CI): -0.07 (-0.45, 0.31), p = 0.710] between MIS-C with and without coronary artery abnormality. Sensitivity analyses were performed to assess stability. No publication bias was detected based on Begg's test. CONCLUSIONS: The key cardiac marker that showed differences between patients with MIS-C/non-severe COVID-19 and between patients with severe/non-severe MIS-C was BNP. Other markers, such as troponin and AST, did not exhibit notable differences in indicating cardiac injury between patients with MIS-C and COVID-19.
Authors: Daniel J Corwin; Laura F Sartori; Kathleen Chiotos; Audrey R Odom John; Keri Cohn; Hamid Bassiri; Edward M Behrens; David T Teachey; Sarah E Henrickson; Caroline J Diorio; Joseph J Zorc; Fran Balamuth Journal: Pediatr Emerg Care Date: 2020-11 Impact factor: 1.454
Authors: Laura A Vella; Josephine R Giles; Amy E Baxter; Derek A Oldridge; Caroline Diorio; Leticia Kuri-Cervantes; Cécile Alanio; M Betina Pampena; Jennifer E Wu; Zeyu Chen; Yinghui Jane Huang; Elizabeth M Anderson; Sigrid Gouma; Kevin O McNerney; Julie Chase; Chakkapong Burudpakdee; Jessica H Lee; Sokratis A Apostolidis; Alexander C Huang; Divij Mathew; Oliva Kuthuru; Eileen C Goodwin; Madison E Weirick; Marcus J Bolton; Claudia P Arevalo; Andre Ramos; C J Jasen; Peyton E Conrey; Samir Sayed; Heather M Giannini; Kurt D'Andrea; Nuala J Meyer; Edward M Behrens; Hamid Bassiri; Scott E Hensley; Sarah E Henrickson; David T Teachey; Michael R Betts; E John Wherry Journal: Sci Immunol Date: 2021-03-02
Authors: Joshua P Lang; Xiaowen Wang; Filipe A Moura; Hasan K Siddiqi; David A Morrow; Erin A Bohula Journal: Am Heart J Date: 2020-05-03 Impact factor: 4.749
Authors: Patrick Davies; Claire Evans; Hari Krishnan Kanthimathinathan; Jon Lillie; Joseph Brierley; Gareth Waters; Mae Johnson; Benedict Griffiths; Pascale du Pré; Zoha Mohammad; Akash Deep; Stephen Playfor; Davinder Singh; David Inwald; Michelle Jardine; Oliver Ross; Nayan Shetty; Mark Worrall; Ruchi Sinha; Ashwani Koul; Elizabeth Whittaker; Harish Vyas; Barnaby R Scholefield; Padmanabhan Ramnarayan Journal: Lancet Child Adolesc Health Date: 2020-07-09
Authors: Elizabeth Whittaker; Alasdair Bamford; Julia Kenny; Myrsini Kaforou; Christine E Jones; Priyen Shah; Padmanabhan Ramnarayan; Alain Fraisse; Owen Miller; Patrick Davies; Filip Kucera; Joe Brierley; Marilyn McDougall; Michael Carter; Adriana Tremoulet; Chisato Shimizu; Jethro Herberg; Jane C Burns; Hermione Lyall; Michael Levin Journal: JAMA Date: 2020-07-21 Impact factor: 157.335
Authors: Daniel McAree; Amanda Hauck; Jennifer Arzu; Michael Carr; Jennifer Acevedo; Ami B Patel; Nazia Husain Journal: Pediatr Cardiol Date: 2022-10-19 Impact factor: 1.838
Authors: Daniela Cihakova; Michael B Streiff; Steven P Menez; Teresa K Chen; Nisha A Gilotra; Erin D Michos; Kieren A Marr; Andrew H Karaba; Matthew L Robinson; Paul W Blair; Maria V Dioverti; Wendy S Post; Andrea L Cox; Annukka A R Antar Journal: Future Virol Date: 2021-09-21 Impact factor: 3.015
Authors: Wael Al Mahmeed; Khalid Al-Rasadi; Yajnavalka Banerjee; Antonio Ceriello; Francesco Cosentino; Massimo Galia; Su-Yen Goh; Peter Kempler; Nader Lessan; Nikolaos Papanas; Ali A Rizvi; Raul D Santos; Anca P Stoian; Peter P Toth; Manfredi Rizzo Journal: Front Cardiovasc Med Date: 2021-12-15